HOB Biotech Group Corp.,Ltd (SHA:688656)
China · Delayed Price · Currency is CNY 147.61
+3.69 (2.56%)
Feb 13, 2026, 3:00 PM CST
SHA:688656 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 377 | 391.86 | 382.83 | 311 | 309.16 | 214.93 |
Other Revenue | 10.48 | 10.48 | 11.57 | 9.39 | 8.55 | 6.93 |
| 387.48 | 402.34 | 394.41 | 320.39 | 317.71 | 221.86 | |
Revenue Growth (YoY) | -3.44% | 2.01% | 23.10% | 0.84% | 43.20% | -14.38% |
Cost of Revenue | 155.01 | 145.16 | 149.41 | 118.14 | 98.55 | 76.4 |
Gross Profit | 232.48 | 257.18 | 244.99 | 202.26 | 219.16 | 145.46 |
Selling, General & Admin | 149.44 | 160.69 | 140.05 | 118.76 | 99.87 | 69.19 |
Research & Development | 44.85 | 45.47 | 46.32 | 38.11 | 31.23 | 23.04 |
Other Operating Expenses | 9.36 | 6.47 | 4.83 | 3.64 | 3.32 | 2.48 |
Operating Expenses | 203.4 | 213.02 | 191.7 | 160.25 | 134.83 | 95.23 |
Operating Income | 29.08 | 44.16 | 53.3 | 42.01 | 84.33 | 50.22 |
Interest Expense | -3.46 | -2.71 | -2.53 | -1.92 | -1.24 | -1.89 |
Interest & Investment Income | 0.75 | 0.89 | 3.4 | 6.95 | 13.08 | 15.3 |
Currency Exchange Gain (Loss) | -0.53 | -0.53 | -0.01 | -0.15 | -0.46 | 0.01 |
Other Non Operating Income (Expenses) | 1.08 | -0.36 | -0.27 | -0.18 | 0 | -0 |
EBT Excluding Unusual Items | 26.92 | 41.46 | 53.89 | 46.71 | 95.72 | 63.65 |
Gain (Loss) on Sale of Investments | - | - | 0.43 | 0.22 | 0.01 | - |
Gain (Loss) on Sale of Assets | 7.79 | -0.75 | 0.03 | -0.47 | -0.08 | -0.37 |
Asset Writedown | -1.1 | -1.1 | - | - | - | - |
Other Unusual Items | 3.8 | 1.43 | 2.28 | 0.02 | 3.48 | 1.82 |
Pretax Income | 37.41 | 41.03 | 56.63 | 46.48 | 99.13 | 65.1 |
Income Tax Expense | 0.98 | 4.23 | 9.29 | 4.83 | 12.93 | 8.49 |
Net Income | 36.43 | 36.8 | 47.33 | 41.65 | 86.19 | 56.62 |
Net Income to Common | 36.43 | 36.8 | 47.33 | 41.65 | 86.19 | 56.62 |
Net Income Growth | 3.32% | -22.24% | 13.64% | -51.68% | 52.24% | -11.31% |
Shares Outstanding (Basic) | 62 | 62 | 63 | 63 | 62 | 47 |
Shares Outstanding (Diluted) | 64 | 63 | 64 | 63 | 62 | 47 |
Shares Change (YoY) | 1.31% | -0.79% | 1.35% | 2.50% | 30.49% | -0.22% |
EPS (Basic) | 0.59 | 0.59 | 0.75 | 0.66 | 1.40 | 1.20 |
EPS (Diluted) | 0.57 | 0.58 | 0.74 | 0.66 | 1.40 | 1.20 |
EPS Growth | 1.98% | -21.62% | 12.12% | -52.86% | 16.67% | -11.11% |
Free Cash Flow | -8.84 | -54.15 | -75.34 | -161.9 | -63.09 | 1.21 |
Free Cash Flow Per Share | -0.14 | -0.85 | -1.18 | -2.56 | -1.02 | 0.03 |
Dividend Per Share | 0.300 | 0.300 | 0.400 | 0.300 | 0.530 | 0.300 |
Dividend Growth | -25.00% | -25.00% | 33.33% | -43.40% | 76.67% | - |
Gross Margin | 60.00% | 63.92% | 62.12% | 63.13% | 68.98% | 65.56% |
Operating Margin | 7.51% | 10.98% | 13.51% | 13.11% | 26.54% | 22.64% |
Profit Margin | 9.40% | 9.15% | 12.00% | 13.00% | 27.13% | 25.52% |
Free Cash Flow Margin | -2.28% | -13.46% | -19.10% | -50.53% | -19.86% | 0.55% |
EBITDA | 72.74 | 83.31 | 86.41 | 68.95 | 104.06 | 65.62 |
EBITDA Margin | 18.77% | 20.71% | 21.91% | 21.52% | 32.76% | 29.58% |
D&A For EBITDA | 43.66 | 39.14 | 33.12 | 26.94 | 19.73 | 15.4 |
EBIT | 29.08 | 44.16 | 53.3 | 42.01 | 84.33 | 50.22 |
EBIT Margin | 7.51% | 10.98% | 13.51% | 13.11% | 26.54% | 22.64% |
Effective Tax Rate | 2.62% | 10.31% | 16.41% | 10.39% | 13.05% | 13.04% |
Revenue as Reported | 387.48 | 402.34 | 394.41 | 320.39 | 317.71 | 221.86 |
Advertising Expenses | - | 10.05 | 9.61 | 8.73 | 6.51 | 5.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.